SIGMA LABS INC (SGLB) Fundamental Analysis & Valuation

NASDAQ:SGLB • US8265985007

1.05
+0.02 (+1.94%)
Last: May 18, 2022, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SGLB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall SGLB gets a fundamental rating of 3 out of 10. We evaluated SGLB against 78 industry peers in the Aerospace & Defense industry. The financial health of SGLB is average, but there are quite some concerns on its profitability. SGLB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. SGLB Profitability Analysis

1.1 Basic Checks

  • In the past year SGLB has reported negative net income.
SGLB Yearly Net Income VS EBIT VS OCF VS FCFSGLB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -2M -4M -6M -8M

1.2 Ratios

Industry RankSector Rank
ROA -76.17%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGLB Yearly ROA, ROE, ROICSGLB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -200 -400 -600 -800

1.3 Margins

Industry RankSector Rank
OM -750.81%
PM (TTM) -721.77%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGLB Yearly Profit, Operating, Gross MarginsSGLB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SGLB Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for SGLB has been increased compared to 1 year ago.
  • SGLB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGLB Yearly Shares OutstandingSGLB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
SGLB Yearly Total Debt VS Total AssetsSGLB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

2.2 Solvency

  • SGLB has an Altman-Z score of 0.74. This is a bad value and indicates that SGLB is not financially healthy and even has some risk of bankruptcy.
  • There is no outstanding debt for SGLB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.74
ROIC/WACCN/A
WACCN/A
SGLB Yearly LT Debt VS Equity VS FCFSGLB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 11.66 indicates that SGLB has no problem at all paying its short term obligations.
  • A Quick Ratio of 10.79 indicates that SGLB has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 11.66
Quick Ratio 10.79
SGLB Yearly Current Assets VS Current LiabilitesSGLB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SGLB Growth Analysis

3.1 Past

  • SGLB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.61%.
  • The Revenue has grown by 18.10% in the past year. This is quite good.
  • The Revenue has been growing by 11.21% on average over the past years. This is quite good.
EPS 1Y (TTM)2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)18.1%
Revenue growth 3Y61.74%
Revenue growth 5Y11.21%
Sales Q2Q%-89.13%

3.2 Future

  • SGLB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.92% yearly.
  • The Revenue is expected to grow by 43.01% on average over the next years. This is a very strong growth
EPS Next Y-32.39%
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%
EPS Next 5Y1.92%
Revenue Next Year-52.74%
Revenue Next 2Y19.03%
Revenue Next 3Y34.08%
Revenue Next 5Y43.01%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGLB Yearly Revenue VS EstimatesSGLB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
SGLB Yearly EPS VS EstimatesSGLB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. SGLB Valuation Analysis

4.1 Price/Earnings Ratio

  • SGLB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SGLB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGLB Price Earnings VS Forward Price EarningsSGLB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.19
SGLB Per share dataSGLB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGLB Dividend Analysis

5.1 Amount

  • SGLB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SGLB Fundamentals: All Metrics, Ratios and Statistics

SIGMA LABS INC

NASDAQ:SGLB (5/18/2022, 8:00:02 PM)

1.05

+0.02 (+1.94%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)04-26
Earnings (Next)07-20
Inst Owners0.19%
Inst Owner Change-98.05%
Ins Owners3.71%
Ins Owner Change0%
Market Cap11.03M
Revenue(TTM)1.24M
Net Income(TTM)-8.95M
Analysts82.86
Price Target3.06 (191.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.89
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB N/A
EV/EBITDA -0.19
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.12
BVpS1.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -750.81%
PM (TTM) -721.77%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.66
Quick Ratio 10.79
Altman-Z 0.74
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y-32.39%
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%
EPS Next 5Y1.92%
Revenue 1Y (TTM)18.1%
Revenue growth 3Y61.74%
Revenue growth 5Y11.21%
Sales Q2Q%-89.13%
Revenue Next Year-52.74%
Revenue Next 2Y19.03%
Revenue Next 3Y34.08%
Revenue Next 5Y43.01%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

SIGMA LABS INC / SGLB FAQ

Can you provide the ChartMill fundamental rating for SIGMA LABS INC?

ChartMill assigns a fundamental rating of 4 / 10 to SGLB.


What is the valuation status of SIGMA LABS INC (SGLB) stock?

ChartMill assigns a valuation rating of 2 / 10 to SIGMA LABS INC (SGLB). This can be considered as Overvalued.


What is the profitability of SGLB stock?

SIGMA LABS INC (SGLB) has a profitability rating of 1 / 10.


Can you provide the financial health for SGLB stock?

The financial health rating of SIGMA LABS INC (SGLB) is 6 / 10.


Is the dividend of SIGMA LABS INC sustainable?

The dividend rating of SIGMA LABS INC (SGLB) is 0 / 10 and the dividend payout ratio is 0%.